Article By:
TalkMarkets Newswire
Wednesday, May 19, 2021 10:04 AM EDT
CNS Pharmaceuticals today announced open enrollment for its potentially pivotal study evaluating the efficacy and safety of Berubicin in the treatment of recurrent GBM.
In this article: CNSP Also: ONTX, RARE, SEEL, AUVI, GTBP
